factors that preclude the use of bevacizumab, and the desire to avoid alopecia and neutropenic fever. For most patients with NS-NSCLC, optimal first-line treatment is a combination of a platinum drug with pemetrexed alone, pemetrexed and bevacizumab, or
Search Results
Ryan D. Gentzler and Jyoti D. Patel
Jacalyn Rosenblatt and David Avigan
risk of death or disease progression compared with the control arm. 55 Adverse events related to elotuzumab have included lymphopenia and infusion reactions, such as fevers and hypertension. 55 An alternative strategy has been the development of NK
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021
Featured Updates to the NCCN Guidelines
Efrat Dotan, Louise C. Walter, Ilene S. Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard, Reshma Jagsi, Nancy L. Keating, Elizabeth Kessler, Thuy Koll, Beatriz Korc-Grodzicki, June M. McKoy, Sumi Misra, Dominic Moon, Tracey O’Connor, Cynthia Owusu, Ashley Rosko, Marcia Russell, Mina Sedrak, Fareeha Siddiqui, Amy Stella, Derek L. Stirewalt, Ishwaria M. Subbiah, William P. Tew, Grant R. Williams, Liz Hollinger, Giby V. George, and Hema Sundar
neutropenic fever and death. 35 , 36 Finally, a HCT-CI score ≥3 was found to be more predictive for a lower overall survival (OS) among patients aged ≥50 years who had undergone allogenic HCT. 37 For older adults with comorbidities, the panel recommends
Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson
/emesis, neuropathy, myelosuppression, and related fever and neutropenia) and the efficacy and convenience of outpatient biweekly delivery favor ABVD for adult oncology practices, the potential for late cardiotoxicity in children and adolescents due to higher
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
Featured Updates to the NCCN Guidelines
Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
(range, 1.9 to ≥21.8 months). The most common adverse effects with pembrolizumab were fatigue, pruritus, diarrhea, anorexia, constipation, nausea, rash, fever, cough, dyspnea, and musculoskeletal pain. Pembrolizumab also may be associated with immune
Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider
Patients are rarely symptomatic; however, some may present with fever. Other more common causes of renal dysfunction, such as dehydration or exposure to nephrotoxins like nonsteroidal anti-inflammatory drugs, contrast agents, bisphosphonates, and proton
Aditi Bagchi, Sandeep K. Dhanda, Paige Dunphy, Edgar Sioson, and Giles W. Robinson
chemotherapy. A preliminary report . Cancer 1987 ; 60 : 173 – 177 . 17. Boogerd W , van der Sande JJ , Moffie D. Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate . J Neurol Neurosurg Psychiatry 1988
-lived memory CD8 T cells from individuals vaccinated for yellow fever. Furthermore, we show that CAR T cells were unable to mount an in vivo recall response after relapse of antigen-positive disease or recovery of endogenous B cells. Conclusions: These
Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar
): peripheral blood lymphocyte counts less than 4 × 10 9 /L; absence of lymphadenopathy (ie, palpable nodes must be ≤1.5 cm in diameter); absence of splenomegaly or hepatomegaly; absence of constitutional symptoms (ie, weight loss, significant fatigue, fevers
Ann M. Berger, Amy Pickar Abernethy, Ashley Atkinson, Andrea M. Barsevick, William S. Breitbart, David Cella, Bernadine Cimprich, Charles Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Phyllis Kaldor, Jennifer A. Ligibel, Barbara A. Murphy, Tracey O'Connor, William F. Pirl, Eve Rodler, Hope S. Rugo, Jay Thomas, and Lynne I. Wagner
neutropenia Thrombocytopenia (low platelets) Anemia (low red blood cells) Fever or active infection Limitations secondary to metastasis or other illnesses The exercise program itself should be individualized based on the patient's age, gender, type